摘要
目的探讨肾炎温阳胶囊联合来氟米特片治疗慢性肾小球肾炎的临床疗效。方法选取2018年3月—2020年3月在焦作市人民医院进行治疗的120例慢性肾小球肾炎患者,根据用药差别分为对照组和治疗组,每组各60例。对照组口服来氟米特片,2片/次,1次/d;治疗组在对照组基础上口服肾炎温阳胶囊,3粒/次,3次/d。两组均治疗14 d后进行效果比较。观察两组的临床疗效,比较两组治疗前后肾功能指标、足细胞标志物和血清学指标的变化情况。结果经治疗,对照组总有效率是81.67%,显著低于治疗组96.67%(P<0.05)。经治疗,两组患者24 h尿蛋白(24 h Upro)、血肌酐(Scr)、尿素氮(BUN)、尿红细胞均较治疗前显著下降(P<0.05),且以治疗组更显著(P<0.05)。经治疗,两组足萼糖蛋白(PCX)、尿足细胞分子(B7-1)均较治疗前显著下降(P<0.05),且以治疗组最著(P<0.05)。经治疗,两组血清胱抑素C(Cys-C)、白细胞介素-17(IL-17)、α1-微球蛋白(α1-MG)、血管内皮生长因子(VEGF)、凝血酶激活的纤溶抑制物(TAFI)水平均显著下降(P<0.05),且以治疗组更显著(P<0.05)。结论肾炎温阳胶囊联合来氟米特治疗慢性肾小球肾炎具有较好的临床疗效,可改善患者肾功能,降低机体炎症反应,减轻足细胞损伤,具有一定的临床推广应用价值。
Objective To explore the clinical effect of Shenyan Wenyang Capsules combined with leflunomide in treatment of chronic glomerulonephritis.Methods 120 Patients with chronic glomerulonephritis admitted to Jiaozuo People's Hospital from March 2018 to March 2020 were divided into control group(60 cases)and treatment group(60 cases)according to the difference of medication.The control group was po administered with Leflunomide Tablets,2 tabltes/time,once daily.The treatment group was po administered with Shenyan Wenyang Capsules on the basis of the control group,3 grains/time,three times daily.All patients were treated for 14 d.The clinical efficacy in two groups were observed,changes of renal functions,podocyte markers and serological indexes before and after treatment were compared between the two groups.Results After treatment,the effective rate of the control group was 81.67%,significantly lower than that of the treatment group 96.67%(P<0.05).After treatment,24 h Upro,Scr,BUN,and RBC in urine were all decreased in two groups,especially in the treatment group(P<0.05).After treatment,PCX and B7-1 in urine of the two groups were significantly decreased,especially in the treatment group(P<0.05).After treatment,the levels of Cys-C,IL-17,α1-MG,VEGF and TAFI in the serum of the two groups were significantly decreased,especially in the treatment group(P<0.05).Conclusion Shenyan Wenyang Capsule combined with leflunomide has good clinical effect,and can significantly improve the renal function of patients with glomerulonephritis,and can reduce the inflammatory response of the body,reduce the damage of podocytes,which has a certain clinical application value.
作者
王媛媛
郭林
常卫华
WANG Yuan-yuan;GUO Lin;CHANG Wei-hua(Department of Nephrology,Jiaozuo People's Hospital,Jiaozuo 454000,China)
出处
《现代药物与临床》
CAS
2020年第7期1426-1429,共4页
Drugs & Clinic
